Navigation Links
Key pathway in end-stage prostate cancer tumor progression blocked
Date:7/20/2010

DALLAS July 22, 2010 Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.

The findings, appearing online and in the August issue of Endocrinology, suggest that this step might one day provide a new avenue of therapy for patients with end-stage prostate cancer. Health care experts estimate that more than 2 million men in the U.S. have prostate cancer, with more than 27,000 deaths related to the disease in 2009.

"We were able to block the androgen response, which is a central pathway for tumor progression," said Dr. Nima Sharifi, assistant professor of internal medicine and the study's senior author.

End-stage prostate tumors typically are treated with hormones that suppress the levels of the androgens, or male hormones like testosterone, that cause prostate cancer cells to grow. Eventually, however, the tumors become resistant to this therapy and resume their growth.

Using prostate cancer cell lines, Dr. Sharifi and his colleagues found that the hormone dehydroepiandrosterone (DHEA) is converted by the tumors into androgens. By blocking the enzyme 3β-hydroxysteroid dehydrogenase (3βHSD), which is responsible for the first enzymatic step that is required to convert DHEA to androgens, researchers were able to shut down the tumors' lifeline.

"Enzymes in general can make great drug targets, so this process conceivably could be targeted for the development of new treatments for end-stage prostate cancer, which has limited therapeutic options right now," said Dr. Sharifi, an investigator in UT Southwestern's Harold C. Simmons Comprehensive Cancer Center. "The goal would be to develop a drug that targets that enzyme to be used for the advanced, incurable stage."

No standard treatments currently target this enzyme, but there is proven clinical evidence that this pathway is central to driving tumor progression.


'/>"/>

Contact: Connie Piloto
connie.piloto@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Scientists find link between estrogen metabolism pathway and breast cancer risk
2. Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways
3. New pathway to cheap insulin
4. A single protein regulates 2 immune pathways
5. Space Coast Cancer Center Selects Via Oncology™ Pathways to Advance Evidence-Based Cancer Care
6. Targeting cell pathway may prevent relapse of leukemia
7. Newly identified proteins critical to FA pathway DNA repair function
8. Cellular pathway could provide evidence of how cancer and obesity are linked
9. Welsh Tree LLC Proudly Presents the Release of the Celtic Pathways CD by Jason Evans, in Time for Saint Patrick's Day
10. Different signaling pathways of cholangiocarcinoma
11. Arsenic exposure activates an oncogenic signaling pathway; leads to increased cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... Scotch Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD ... with the treatment of acute or chronic problems, I focus on preventative care with all ... patient. If you have any questions, always feel free to contact my office and my ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Surgical Drainage Device ... tubes used to remove excess liquid and air. The ... urine, bile or lymph. Surgical drains are used in ... as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. ... to prevent accumulation of fluid e.g. blood or pus. ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: